DOCSLIB.ORG

Discovery of a Nucleocytoplasmic O-Mannose Glycoproteome in Yeast

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Discovery of a Nucleocytoplasmic O-Mannose Glycoproteome in Yeast Discovery of a nucleocytoplasmic O-mannose glycoproteome in yeast Adnan Halima,1, Ida Signe Bohse Larsena, Patrick Neubertb, Hiren Jitendra Joshia, Bent Larsen Petersena,c, Sergey Y. Vakhrusheva, Sabine Strahlb, and Henrik Clausena,1 aCopenhagen Center for Glycomics, Departments of Cellular and Molecular Medicine, Faculty of Health Sciences, University of Copenhagen, DK-2200 Copenhagen N, Denmark; bCentre for Organismal Studies (COS), University of Heidelberg, D-69120 Heidelberg, Germany; and cDepartment of Plant and Environmental Sciences, University of Copenhagen, DK-1871 Frederiksberg C, Denmark Edited by Stuart A. Kornfeld, Washington University School of Medicine, St. Louis, MO, and approved October 12, 2015 (received for review June 16, 2015) Dynamic cycling of N-Acetylglucosamine (GlcNAc) on serine and orthologous OGT/OGA genes is yeast, although OGA orthologs threonine residues (O-GlcNAcylation) is an essential process in all have not been identified in plants. Yeast uses primarily Ser and eukaryotic cells except yeast, including Saccharomyces cerevisiae Thr for phosphorylation, with tyrosine (Tyr) phosphorylation and Schizosaccharomyces pombe. O-GlcNAcylation modulates signaling being used to an extremely low extent (10). This is in contrast to and cellular processes in an intricate interplay with protein phosphor- other eukaryotic cells that phosphorylate all three residues for ylation and serves as a key sensor of nutrients by linking the hexos- extensive and vital signaling. It has been a longstanding puzzle amine biosynthetic pathway to cellular signaling. A longstanding why in yeast the coregulatory functions of O-GlcNAcylation conundrum has been how yeast survives without O-GlcNAcylation in are apparently not required or whether another type of protein light of its similar phosphorylation signaling system. We previously O-glycosylation, such as O-linked mannose (O-Man), takes on developed a sensitive lectin enrichment and mass spectrometry work- this role (6). flow for identification of the human O-linked mannose (O-Man) glyco- All eukaryotes except nematodes and plants have a well- proteome and used this to identify a pleothora of O-Man glycoproteins characterized O-Man glycosylation machinery for proteins traf- in human cell lines including the large family of cadherins and proto- ficking the secretory pathway, and the enzymes involved in this cadherins. Here, we applied the workflow to yeast with the aim to process are multitransmembrane-spanning dolichol phosphate characterize the yeast O-Man glycoproteome, and in doing so, we β-D-Man (Dol-P-Man):protein O-mannosyltransferases (PMTs) discovered hitherto unknown O-Man glycosites on nuclear, cytoplas- using the membrane-associated Dol-P-Man donor substrate and mic, and mitochondrial proteins in S. cerevisiae and S. pombe.Such transferring a single Man residue to selected Ser and Thr residues O-Man glycoproteins were not found in our analysis of human cell of proteins. These enzymes are located in the ER, with their cat- lines. However, the type of yeast O-Man nucleocytoplasmic proteins alytic domains oriented into the lumen (11, 12). Higher eukaryotic and the localization of identifiedO-Manresiduesmirrorthatofthe cells have two PMT isoenzymes (POMT1 and POMT2), and the O-GlcNAc glycoproteome found in other eukaryotic cells, indicating initial O-Man glycans are elongated, branched, and capped by sialic that the two different types of O-glycosylations serve the same im- acids by a series of glycosyltransferases. Deficiencies in many of the portant biological functions. The discovery opens for exploration of enzymes involved in protein O-mannosylation in humans under- the enzymatic machinery that is predicted to regulate the nucleocy- lie a group of congenital muscular dystrophies (13). Yeast, in toplasmic O-Man glycosylations. It is likely that manipulation of this contrast, have a family of at least six PMTs, and the initial Man type of O-Man glycosylation will have wide applications for yeast bioprocessing. Significance glycoproteomics | O-glycosylation | yeast | mass spectrometry | signaling Nucleocytoplasmic dynamic cycling of N-Acetylglucosamine (GlcNAc) on serine and threonine residues (O-GlcNAcylation) and phos- ll eukaryotic cells except yeast harbor a simple type of phorylation coregulate important cellular processes in all eukaryotic Aprotein O-glycosylation designated O-GlcNAcylation [dy- organisms except yeast, including Saccharomyces cerevisiae namic cycling of N-Acetylglucosamine (GlcNAc) on serine (Ser) and Schizosaccharomyces pombe. The lack of an equivalent and threonine (Thr) residues] in the cytosol and nucleus (1). nucleocytoplasmic O-glycosylation system in yeast has been O-GlcNAcylation is an essential process involving addition and difficult to explain given that O-GlcNAcylation is an essential removal of a single GlcNAc at Ser and Thr residues of nuclear, modification in higher organisms. Here, we reveal that yeast – cytoplasmic, and mitochondrial proteins (2 5). O-GlcNAcylation use O-linked mannose to modify nucleocytoplasmic proteins on is a widespread modification found on, for example, nucleo- evolutionary-conserved regions and sites normally occupied by porins, transcription factors, kinases, and cytoskeletal and O-GlcNAc in higher eukaryotes. The results presented in this chromatin proteins; it is involved in a plethora of biological study open new avenues for exploration of nutrient sensing processes and believed to play causal roles in diabetes, cancer, and signaling events based on nucleocytoplasmic O-glycosylation cardiovascular, and Alzheimer’s disease (6–8). Sites of O- in yeast. GlcNAcylation are often found at or in close proximity to protein phosphorylation sites, and the intricate interplay between both Author contributions: A.H., S.S., and H.C. designed research; A.H., I.S.B.L., P.N., and B.L.P. modifications is known to modulate many important processes in performed research; A.H., I.S.B.L., P.N., H.J.J., S.Y.V., S.S., and H.C. analyzed data; and A.H. cells (8, 9). The transfer of GlcNAc to proteins is carried out by the and H.C. wrote the paper. The authors declare no conflict of interest. O-GlcNAc transferase (OGT) using uridine diphosphate α-D- GlcNAc (UDP-GlcNAc) as a donor substrate, and a second hy- This article is a PNAS Direct Submission. drolytic enzyme, O-GlcNAcase (OGA), is available to remove the Data deposition: The mass spectrometry proteomics data have been deposited in the ProteomeXchange Consortium via the PRoteomics IDEntifications (PRIDE) Partner Repos- GlcNAc monosaccharide in a regulated dynamic process (4, 5). itory (accession no. PXD002924). Discovered over 30 years ago, the OGT/OGA enzyme pair was 1 To whom correspondence may be addressed. Email: [email protected] or halim@sund. initially identified in mammals, but subsequent work has demon- ku.dk. strated O-GlcNAcylation in bacteria, filamentous fungi, plants, and This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. metazoans. The only eukaryotic cell type without identifiable 1073/pnas.1511743112/-/DCSupplemental. 15648–15653 | PNAS | December 22, 2015 | vol. 112 | no. 51 www.pnas.org/cgi/doi/10.1073/pnas.1511743112 Downloaded by guest on October 1, 2021 monosaccharide is extended only by additional mannose residues from total cell lysates. In striking contrast to our studies with through the actions of Golgi resident mannosyltransferases of the humancelllines,weinadditiontoproteinsenteringthese- KTR/MNT and MNN family that use GDP α-D-Man (GDP-Man) cretory pathway also identified a large number of O-Man as a donor substrate (11). The O-Man glycosylation and the action proteins annotated as classical nuclear, cytosolic, or mito- of multiple PMTs are essential for yeast (14), and O-Man plays chondrial proteins that are not expected to be exposed to the major roles in maintaining yeast cell wall integrity (15). known O-Man glycosylation machinery in the secretory path- Our knowledge of the proteins undergoing O-Man glycosylation way. The nucleocytoplasmic O-Man glycosites were located on in yeast and the specific sites of glycosylation is limited (11, 12), but proteins and in positions resembling that of the O-GlcNAcy- recently we developed a glycoproteomic strategy to probe the lation process in higher eukaryotes. Here, we describe this O- O-Man glycoproteome of human cells using genetic engineer- Man glycoproteome and suggest that the nucleocytoplasmic O- ing to simplify the O-glycan structures, the so-called “SimpleCell” Man modifications in yeast represent the missing equivalent to strategy, in combination with Concanavalin A (ConA) lectin chro- the O-GlcNAcylation process of higher eukaryotes, and future matography for enrichment of glycopeptides and mass spec- studies can now address the biosynthetic machinery and trometric sequencing (16). This resulted in identification of a biological functions. large number of O-Man glycoproteins and O-Man glycosites, demonstrating, for example, that cadherins and protocadherins Results and Discussion are major carriers of O-Man glycans. In the present study, we Probing the O-Man Glycoproteome of Saccharomyces cerevisiae and modified this strategy to probe the yeast O-Man glycoproteome Schizosaccharomyces pombe. Because yeast is known to produce A WT KRE2∆KTR1∆KTR3∆ N-linked O-linked Tryptic digests O-glycopeptides + PNGase F ConA + Trypsin LWAC MS Mannose N-Acetylglucosamine B C D CELL BIOLOGY WT Mannitol Sorbitol α-mannosidase 100 24 - + - + 146 91 Total 80
Load more

Recommended publications
  • Broad and Thematic Remodeling of the Surface Glycoproteome on Isogenic
    bioRxiv preprint doi: https://doi.org/10.1101/808139; this version posted October 17, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Broad and thematic remodeling of the surface glycoproteome on isogenic cells transformed with driving proliferative oncogenes Kevin K. Leung1,5, Gary M. Wilson2,5, Lisa L. Kirkemo1, Nicholas M. Riley2,4, Joshua J. Coon2,3, James A. Wells1* 1Department of Pharmaceutical Chemistry, UCSF, San Francisco, CA, USA Departments of Chemistry2 and Biomolecular Chemistry3, University of Wisconsin- Madison, Madison, WI, 53706, USA 4Present address Department of Chemistry, Stanford University, Stanford, CA, 94305, USA 5These authors contributed equally *To whom correspondence should be addressed bioRxiv preprint doi: https://doi.org/10.1101/808139; this version posted October 17, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract: The cell surface proteome, the surfaceome, is the interface for engaging the extracellular space in normal and cancer cells. Here We apply quantitative proteomics of N-linked glycoproteins to reveal how a collection of some 700 surface proteins is dramatically remodeled in an isogenic breast epithelial cell line stably expressing any of six of the most prominent proliferative oncogenes, including the receptor tyrosine kinases, EGFR and HER2, and downstream signaling partners such as KRAS, BRAF, MEK and AKT.
    [Show full text]
  • The Effects of Acute Nicotinamide Riboside Supplementation
    THE EFFECTS OF ACUTE NICOTINAMIDE RIBOSIDE SUPPLEMENTATION ON SUBSTRATE UTILISATION AND 5KM TIME-TRIAL PERFORMANCE By ELIZABETH LOUISE GRAY A thesis submitted to The University of Birmingham for the degree of MASTERS BY RESEARCH School of Sport, Exercise and Rehabilitation Sciences College of Life and Environmental Studies University of Birmingham August 2018 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. ABSTRACT Nicotinamide Riboside (NR) administration has been shown to increase fat oxidation and improve endurance performance in rodents, whilst recent research has proven it is safe for human consumption. The present study aimed to investigate the influence of acute NR supplementation on substrate utilisation and exercise performance in humans. In this counter-balanced, crossover design study, eleven recreationally-active males performed a 60-minute bout of cycling at 55% VO2max, followed by a 5km time-trial. Participants completed this twice during visits separated by at least one week, once following the consumption of 1000mg NR, and the other following placebo consumption. The contribution of fat oxidation to total substrate utilisation was not significantly different between the NR and placebo conditions during steady-state exercise (22.3±9.0% and 19.6±7.3%, respectively; p < 0.05).
    [Show full text]
  • Congenital Disorders of Glycosylation from a Neurological Perspective
    brain sciences Review Congenital Disorders of Glycosylation from a Neurological Perspective Justyna Paprocka 1,* , Aleksandra Jezela-Stanek 2 , Anna Tylki-Szyma´nska 3 and Stephanie Grunewald 4 1 Department of Pediatric Neurology, Faculty of Medical Science in Katowice, Medical University of Silesia, 40-752 Katowice, Poland 2 Department of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland; [email protected] 3 Department of Pediatrics, Nutrition and Metabolic Diseases, The Children’s Memorial Health Institute, W 04-730 Warsaw, Poland; [email protected] 4 NIHR Biomedical Research Center (BRC), Metabolic Unit, Great Ormond Street Hospital and Institute of Child Health, University College London, London SE1 9RT, UK; [email protected] * Correspondence: [email protected]; Tel.: +48-606-415-888 Abstract: Most plasma proteins, cell membrane proteins and other proteins are glycoproteins with sugar chains attached to the polypeptide-glycans. Glycosylation is the main element of the post- translational transformation of most human proteins. Since glycosylation processes are necessary for many different biological processes, patients present a diverse spectrum of phenotypes and severity of symptoms. The most frequently observed neurological symptoms in congenital disorders of glycosylation (CDG) are: epilepsy, intellectual disability, myopathies, neuropathies and stroke-like episodes. Epilepsy is seen in many CDG subtypes and particularly present in the case of mutations
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Chem331 Glycogen Metabolism
    Glycogen metabolism Glycogen review - 1,4 and 1,6 α-glycosidic links ~ every 10 sugars are branched - open helix with many non-reducing ends. Effective storage of glucose Glucose storage Liver glycogen 4.0% 72 g Muscle glycogen 0.7% 245 g Blood Glucose 0.1% 10 g Large amount of water associated with glycogen - 0.5% of total weight Glycogen stored in granules in cytosol w/proteins for synthesis, degradation and control There are very different means of control of glycogen metabolism between liver and muscle Glycogen biosynthetic and degradative cycle Two different pathways - which do not share enzymes like glycolysis and gluconeogenesis glucose -> glycogen glycogenesis - biosynthetic glycogen -> glucose 1-P glycogenolysis - breakdown Evidence for two paths - Patients lacking phosphorylase can still synthesize glycogen - hormonal regulation of both directions Glycogenolysis (glycogen breakdown)- Glycogen Phosphorylase glycogen (n) + Pi -> glucose 1-p + glycogen (n-1) • Enzyme binds and cleaves glycogen into monomers at the end of the polymer (reducing ends of glycogen) • Dimmer interacting at the N-terminus. • rate limiting - controlled step in glycogen breakdown • glycogen phosphorylase - cleavage of 1,4 α glycosidic bond by Pi NOT H2O • Energy of phosphorolysis vs. hydrolysis -low standard state free energy change -transfer potential -driven by Pi concentration -Hydrolysis would require additional step s/ cost of ATP - Think of the difference between adding a phosphate group with hydrolysis • phosphorylation locks glucose in cell (imp. for muscle) • Phosphorylase binds glycogen at storage site and the catalytic site is 4 to 5 glucose residues away from the catalytic site. • Phosphorylase removes 1 residue at a time from glycogen until 4 glucose residues away on either side of 1,6 branch point – stericaly hindered by glycogen storage site • Cleaves without releasing at storage site • general acid/base catalysts • Inorganic phosphate attacks the terminal glucose residue passing through an oxonium ion intermediate.
    [Show full text]
  • Viruses Like Sugars: How to Assess Glycan Involvement in Viral Attachment
    microorganisms Review Viruses Like Sugars: How to Assess Glycan Involvement in Viral Attachment Gregory Mathez and Valeria Cagno * Institute of Microbiology, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland; [email protected] * Correspondence: [email protected] Abstract: The first step of viral infection requires interaction with the host cell. Before finding the specific receptor that triggers entry, the majority of viruses interact with the glycocalyx. Identifying the carbohydrates that are specifically recognized by different viruses is important both for assessing the cellular tropism and for identifying new antiviral targets. Advances in the tools available for studying glycan–protein interactions have made it possible to identify them more rapidly; however, it is important to recognize the limitations of these methods in order to draw relevant conclusions. Here, we review different techniques: genetic screening, glycan arrays, enzymatic and pharmacological approaches, and surface plasmon resonance. We then detail the glycan interactions of enterovirus D68 and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), highlighting the aspects that need further clarification. Keywords: attachment receptor; viruses; glycan; sialic acid; heparan sulfate; HBGA; SARS-CoV-2; EV-D68 Citation: Mathez, G.; Cagno, V. Viruses Like Sugars: How to Assess 1. Introduction Glycan Involvement in Viral This review focuses on methods for assessing the involvement of carbohydrates in Attachment. Microorganisms 2021, 9, viral attachment and entry into the host cell. Viruses often bind to entry receptors that are 1238. https://doi.org/10.3390/ not abundant on the cell surface; to increase their chances of finding them, they initially microorganisms9061238 bind to attachment receptors comprising carbohydrates that are more widely expressed.
    [Show full text]
  • Human Induced Pluripotent Stem Cell–Derived Podocytes Mature Into Vascularized Glomeruli Upon Experimental Transplantation
    BASIC RESEARCH www.jasn.org Human Induced Pluripotent Stem Cell–Derived Podocytes Mature into Vascularized Glomeruli upon Experimental Transplantation † Sazia Sharmin,* Atsuhiro Taguchi,* Yusuke Kaku,* Yasuhiro Yoshimura,* Tomoko Ohmori,* ‡ † ‡ Tetsushi Sakuma, Masashi Mukoyama, Takashi Yamamoto, Hidetake Kurihara,§ and | Ryuichi Nishinakamura* *Department of Kidney Development, Institute of Molecular Embryology and Genetics, and †Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; ‡Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Hiroshima, Japan; §Division of Anatomy, Juntendo University School of Medicine, Tokyo, Japan; and |Japan Science and Technology Agency, CREST, Kumamoto, Japan ABSTRACT Glomerular podocytes express proteins, such as nephrin, that constitute the slit diaphragm, thereby contributing to the filtration process in the kidney. Glomerular development has been analyzed mainly in mice, whereas analysis of human kidney development has been minimal because of limited access to embryonic kidneys. We previously reported the induction of three-dimensional primordial glomeruli from human induced pluripotent stem (iPS) cells. Here, using transcription activator–like effector nuclease-mediated homologous recombination, we generated human iPS cell lines that express green fluorescent protein (GFP) in the NPHS1 locus, which encodes nephrin, and we show that GFP expression facilitated accurate visualization of nephrin-positive podocyte formation in
    [Show full text]
  • Prenatal Testing Requisition Form
    BAYLOR MIRACA GENETICS LABORATORIES SHIP TO: Baylor Miraca Genetics Laboratories 2450 Holcombe, Grand Blvd. -Receiving Dock PHONE: 800-411-GENE | FAX: 713-798-2787 | www.bmgl.com Houston, TX 77021-2024 Phone: 713-798-6555 PRENATAL COMPREHENSIVE REQUISITION FORM PATIENT INFORMATION NAME (LAST,FIRST, MI): DATE OF BIRTH (MM/DD/YY): HOSPITAL#: ACCESSION#: REPORTING INFORMATION ADDITIONAL PROFESSIONAL REPORT RECIPIENTS PHYSICIAN: NAME: INSTITUTION: PHONE: FAX: PHONE: FAX: NAME: EMAIL (INTERNATIONAL CLIENT REQUIREMENT): PHONE: FAX: SAMPLE INFORMATION CLINICAL INDICATION FETAL SPECIMEN TYPE Pregnancy at risk for specific genetic disorder DATE OF COLLECTION: (Complete FAMILIAL MUTATION information below) Amniotic Fluid: cc AMA PERFORMING PHYSICIAN: CVS: mg TA TC Abnormal Maternal Screen: Fetal Blood: cc GESTATIONAL AGE (GA) Calculation for AF-AFP* NTD TRI 21 TRI 18 Other: SELECT ONLY ONE: Abnormal NIPT (attach report): POC/Fetal Tissue, Type: TRI 21 TRI 13 TRI 18 Other: Cultured Amniocytes U/S DATE (MM/DD/YY): Abnormal U/S (SPECIFY): Cultured CVS GA ON U/S DATE: WKS DAYS PARENTAL BLOODS - REQUIRED FOR CMA -OR- Maternal Blood Date of Collection: Multiple Pregnancy Losses LMP DATE (MM/DD/YY): Parental Concern Paternal Blood Date of Collection: Other Indication (DETAIL AND ATTACH REPORT): *Important: U/S dating will be used if no selection is made. Name: Note: Results will differ depending on method checked. Last Name First Name U/S dating increases overall screening performance. Date of Birth: KNOWN FAMILIAL MUTATION/DISORDER SPECIFIC PRENATAL TESTING Notice: Prior to ordering testing for any of the disorders listed, you must call the lab and discuss the clinical history and sample requirements with a genetic counselor.
    [Show full text]
  • Glycogenosis Due to Liver and Muscle Phosphorylase Kinase Deficiency
    Pediat. Res. 15: 299-303 (198 1) genetics muscle glycogenosis phosphorylase kinase deficiency liver Glycogenosis Due to Liver and Muscle Phosphorylase Kinase Deficiency N. BASHAN. T. C. IANCU. A. LERNER. D. FRASER, R. POTASHNIK. AND S. W. MOSES'"' Pediatric Research Laborarorv. Soroka Medical Center. Iaculr~of Health Sciences. Ben-Gurion Universi!,' of Negev. Beer-Sheva, and Department of Pediatrics. Carmel Hospiral. Huifa. Israel Summary hepatomegaly. The family history disclosed that two sisters were similarly affected, whereas one older brother was apparently A four-year-old Israeli Arab boy was found to have glycogen healthy. accumulation in both liver and muscle without clinical symptoms. Past history was unremarkable. The patient's height was below Liver phosphorylase kinase (PK) activity was 20% of normal, the third percentile for his age in contrast to a normal weight. He resulting in undetectable activity of phosphorylase a. Muscle PK had a doll face and a protuberant abdomen. The liver was palpable activity was about 25% of normal, resulting in a marked decrease 9 cm below the costal margin. Slight muscular hypotonia and of phosphorylase a activity. weakness were noticeable with normal tendon reflexes. He had Two sisters showed a similar pattern, whereas one brother had slightly abnormal liver function tests. a fasting blood sugar of 72 normal PK activity. The patient's liver protein kinase activity was mg %, a normal glucagon test. and no lactic acidemia or uricemia normal. Addition of exogenous protein kinase did not affect PK but slight lipidemia. Electronmicroscopic studies of a liver biopsy activity, whereas exogenous PK restored phosphorylase activity revealed marked deposition of glycogen.
    [Show full text]
  • Myo-Glyco Disease Biology: Genetic Myopathies Caused by Abnormal Glycan Synthesis and Degradation
    Journal of Neuromuscular Diseases 6 (2019) 175–187 175 DOI 10.3233/JND-180369 IOS Press Review Myo-Glyco disease Biology: Genetic Myopathies Caused by Abnormal Glycan Synthesis and Degradation Motoi Kanagawa∗ Division of Molecular Brain Science, Kobe University Graduate School of Medicine, Japan Abstract. Glycosylation is a major form of post-translational modification and plays various important roles in organisms by modifying proteins or lipids, which generates functional variability and can increase their stability. Because of the physiological importance of glycosylation, defects in genes encoding proteins involved in glycosylation or glycan degradation are sometimes associated with human diseases. A number of genetic neuromuscular diseases are caused by abnormal glycan modification or degeneration. Heterogeneous and complex modification machinery, and difficulties in structural and functional analysis of glycans have impeded the understanding of how glycosylation contributes to pathology. However, recent rapid advances in glycan and genetic analyses, as well as accumulating genetic and clinical information have greatly contributed to identifying glycan structures and modification enzymes, which has led to breakthroughs in the understanding of the molecular pathogenesis of various diseases and the possible development of therapeutic strategies. For example, studies on the relationship between glycosylation and muscular dystrophy in the last two decades have significantly impacted the fields of glycobiology and neuromyology. In this review, the basis of glycan structure and biosynthesis will be briefly explained, and then molecular pathogenesis and therapeutic concepts related to neuromuscular diseases will be introduced from the point of view of the life cycle of a glycan molecule. Keywords: Glycosylation, muscular dystrophy, neuromuscular disease, therapeutic strategy STRUCTURE AND CELL BIOLOGY OF of a glycoconjugate, such as a glycoprotein and GLYCANS – AN OVERVIEW glycolipid.
    [Show full text]
  • Muscle Glycogen Phosphorylase and Its Functional Partners in Health and Disease
    cells Review Muscle Glycogen Phosphorylase and Its Functional Partners in Health and Disease Marta Migocka-Patrzałek * and Magdalena Elias Department of Animal Developmental Biology, Faculty of Biological Sciences, University of Wroclaw, 50-335 Wroclaw, Poland; [email protected] * Correspondence: [email protected] Abstract: Glycogen phosphorylase (PG) is a key enzyme taking part in the first step of glycogenolysis. Muscle glycogen phosphorylase (PYGM) differs from other PG isoforms in expression pattern and biochemical properties. The main role of PYGM is providing sufficient energy for muscle contraction. However, it is expressed in tissues other than muscle, such as the brain, lymphoid tissues, and blood. PYGM is important not only in glycogen metabolism, but also in such diverse processes as the insulin and glucagon signaling pathway, insulin resistance, necroptosis, immune response, and phototransduction. PYGM is implicated in several pathological states, such as muscle glycogen phosphorylase deficiency (McArdle disease), schizophrenia, and cancer. Here we attempt to analyze the available data regarding the protein partners of PYGM to shed light on its possible interactions and functions. We also underline the potential for zebrafish to become a convenient and applicable model to study PYGM functions, especially because of its unique features that can complement data obtained from other approaches. Keywords: PYGM; muscle glycogen phosphorylase; functional protein partners; glycogenolysis; McArdle disease; cancer; schizophrenia Citation: Migocka-Patrzałek, M.; Elias, M. Muscle Glycogen Phosphorylase and Its Functional Partners in Health and Disease. Cells 1. Introduction 2021, 10, 883. https://doi.org/ The main energy substrate in animal tissues is glucose, which is stored in the liver and 10.3390/cells10040883 muscles in the form of glycogen, a polymer consisting of glucose molecules.
    [Show full text]
  • WO 2017/054086 Al 6 April 2017 (06.04.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/054086 Al 6 April 2017 (06.04.2017) P O P C T (51) International Patent Classification: (74) Agent: TANDAN, Susan; Gowling WLG (Canada) LLP, C12N 5/ 0 (2006.01) C07K 14/47 (2006.01) One Main Street West, Hamilton, Ontario L8P 4Z5 (CA). A61K 31/7088 (2006.01) C07K 14/705 (2006.01) (81) Designated States (unless otherwise indicated, for every A61K 38/46 (2006.01) C07K 19/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 48/00 (2006.01) C12N 15/12 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 9/00 (2006.01) C12N 15/62 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, A61P 21/00 (2006.01) C12N 15/85 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61P 3/00 (2006.01) C12N 15/87 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, PCT/CA201 6/05 1141 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (22) International Filing Date: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, 30 September 2016 (30.09.201 6) TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (25) Filing Language: English ZW.
    [Show full text]